| First Author | Medeiros R | Year | 2011 |
| Journal | Am J Pathol | Volume | 179 |
| Issue | 2 | Pages | 980-91 |
| PubMed ID | 21704011 | Mgi Jnum | J:174403 |
| Mgi Id | MGI:5085973 | Doi | 10.1016/j.ajpath.2011.04.041 |
| Citation | Medeiros R, et al. (2011) Loss of muscarinic m(1) receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am J Pathol 179(2):980-91 |
| abstractText | Alzheimer's disease (AD) is pathologically characterized by tau-laden neurofibrillary tangles and beta-amyloid deposits. Dysregulation of cholinergic neurotransmission has been implicated in AD pathogenesis, contributing to the associated memory impairments; yet, the exact mechanisms remain to be defined. Activating the muscarinic acetylcholine M(1) receptors (M(1)Rs) reduces AD-like pathological features and enhances cognition in AD transgenic models. To elucidate the molecular mechanisms by which M(1)Rs affect AD pathophysiological features, we crossed the 3xTgAD and transgenic mice expressing human Swedish, Dutch, and Iowa triple-mutant amyloid precursor protein (Tg-SwDI), two widely used animal models, with the M(1)R(-/-) mice. Our data show that M(1)R deletion in the 3xTgAD and Tg-SwDI mice exacerbates the cognitive impairment through mechanisms dependent on the transcriptional dysregulation of genes required for memory and through acceleration of AD-related synaptotoxicity. Ablating the M(1)R increased plaque and tangle levels in the brains of 3xTgAD mice and elevated cerebrovascular deposition of fibrillar Abeta in Tg-SwDI mice. Notably, tau hyperphosphorylation and potentiation of amyloidogenic processing in the mice with AD lacking M(1)R were attributed to changes in the glycogen synthase kinase 3beta and protein kinase C activities. Finally, deleting the M(1)R increased the astrocytic and microglial response associated with Abeta plaques. Our data highlight the significant role that disrupting the M(1)R plays in exacerbating AD-related cognitive decline and pathological features and provide critical preclinical evidence to justify further development and evaluation of selective M(1)R agonists for treating AD. |
